

Yann Touchefeu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1639246/publications.pdf>

Version: 2024-02-01

75
papers

1,854
citations

304368

22
h-index

288905

40
g-index

78
all docs

78
docs citations

78
times ranked

3409
citing authors

#	ARTICLE	IF	CITATIONS
1	Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis – current evidence and potential clinical applications. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 409-421.	1.9	331
2	Pathological lesions in colonic biopsies during Parkinson's disease. <i>Gut</i> , 2008, 57, 1741-1743.	6.1	192
3	Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma. <i>JAMA Oncology</i> , 2020, 6, 51.	3.4	176
4	Oncolytic viruses in radiation oncology. <i>Radiotherapy and Oncology</i> , 2011, 99, 262-270.	0.3	57
5	Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study. <i>International Journal of Cancer</i> , 2020, 147, 285-296.	2.3	56
6	Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis of solid pancreatic masses: the impact on patient management strategy. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 1070-1077.	1.9	46
7	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin. <i>British Journal of Surgery</i> , 2018, 105, 668-676.	0.1	44
8	Options for metastatic colorectal cancer beyond the second line of treatment. <i>Digestive and Liver Disease</i> , 2014, 46, 105-112.	0.4	42
9	Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in V600D/EBRAF mutant melanoma depends on JNK and TNF- α signaling. <i>Oncogene</i> , 2014, 33, 1700-1712.	2.6	41
10	Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>BJS Open</i> , 2019, 3, 195-202.	0.7	41
11	Distribution of Bacterial β -1,3-Galactosyltransferase Genes in the Human Gut Microbiome. <i>Frontiers in Immunology</i> , 2019, 10, 3000.	2.2	39
12	Review article: gene therapy, recent developments and future prospects in gastrointestinal oncology. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 953-968.	1.9	37
13	Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. <i>British Journal of Cancer</i> , 2018, 118, 325-330.	2.9	37
14	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. <i>European Journal of Cancer</i> , 2019, 111, 94-106.	1.3	36
15	Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 454-465.	3.7	36
16	Radiovirotherapy: Principles and Prospects in Oncology. <i>Current Pharmaceutical Design</i> , 2012, 18, 3313-3320.	0.9	33
17	Colorectal Cancer Cells Adhere to and Migrate Along the Neurons of the Enteric Nervous System. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 5, 31-49.	2.3	32
18	Pancreatic carcinoma: Key-points from diagnosis to treatment. <i>Diagnostic and Interventional Imaging</i> , 2016, 97, 1207-1223.	1.8	28

#	ARTICLE	IF	CITATIONS
19	Oncolytic Vaccinia virus and radiotherapy in head and neck cancer. <i>Oral Oncology</i> , 2013, 49, 108-118.	0.8	27
20	Hamartomatous Tumors in the Gastrointestinal Tract. <i>Gastrointestinal Tumors</i> , 2015, 2, 65-74.	0.3	27
21	Optimising measles virus-guided radiovirotherapy with external beam radiotherapy and specific checkpoint kinase 1 inhibition. <i>Radiotherapy and Oncology</i> , 2013, 108, 24-31.	0.3	25
22	Hepatic Arterial Infusion Chemotherapy for Unresectable Liver Metastases of Colorectal Cancer: A Multicenter Retrospective Study. <i>Clinical Colorectal Cancer</i> , 2017, 16, 308-315.	1.0	25
23	Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 826-830.	0.8	24
24	Hepatic arterial infusion in the management of colorectal cancer liver metastasis: Current and future perspectives. <i>Digestive and Liver Disease</i> , 2018, 50, 220-225.	0.4	24
25	Outcomes of first-line endoscopic management for patients with sigmoid volvulus. <i>Digestive and Liver Disease</i> , 2019, 51, 386-390.	0.4	21
26	Pembrolizumab for the treatment of colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 219-226.	1.4	21
27	Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches. <i>Frontiers in Medicine</i> , 2019, 6, 124.	1.2	20
28	Antireflux versus conventional self-expanding metallic Stents (SEMS) for distal esophageal cancer: results of a multicenter randomized trial. <i>Endoscopy International Open</i> , 2016, 04, E730-E736.	0.9	16
29	Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 874-882.	3.3	16
30	Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer. <i>Digestive and Liver Disease</i> , 2014, 46, 283-286.	0.4	15
31	Anterograde colonic irrigations by percutaneous endoscopic caecostomy in refractory colorectal functional disorders. <i>International Journal of Colorectal Disease</i> , 2019, 34, 169-175.	1.0	15
32	First pancreatic perivascular epithelioid cell tumor (PEComa) treated by mTOR inhibitor. <i>Pancreatology</i> , 2019, 19, 566-568.	0.5	13
33	Prevalence, Characteristics and Endoscopic Management of Gastric Premalignant Lesions in France. <i>Digestive Diseases</i> , 2020, 38, 286-292.	0.8	13
34	Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 663-668.	0.7	12
35	Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4) Tj ETQq1 1107843141gBT / Oel	1.0	12
36	Long-Term Follow-up of Gastric Precancerous Lesions in a Low GC Incidence Area. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00237.	1.3	12

#	ARTICLE	IF	CITATIONS
37	Oxaliplatin and 5-Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A Multicenter National Retrospective Study from the French Group of Endocrine Tumors. <i>Neuroendocrinology</i> , 2022, 112, 537-546.	1.2	12
38	Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with 18FDG PET-CT. <i>Oncotarget</i> , 2018, 9, 27502-27513.	0.8	12
39	Review article: antitumoural immunity in colorectal cancer – current and potential future implications in clinical practice. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 3-15.	1.9	10
40	Concomitant decrease of double-positive lymphocyte population CD4CD8 ⁺ and Faecalibacterium prausnitzii in patients with colorectal cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 149-156.	0.8	10
41	Prognostic factors of colorectal cancer patients with brain metastases. <i>Radiotherapy and Oncology</i> , 2021, 158, 67-73.	0.3	9
42	A large multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancers with microsatellite instability.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3536-3536.	0.8	9
43	Can PPH3 be helpful to assess the discordant grade in primary and metastatic enteropancreatic neuroendocrine tumors?. <i>Endocrine</i> , 2016, 53, 395-401.	1.1	8
44	Clinical, histological, and molecular risk factors for cancer recurrence in patients with stage II colon cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1394-1399.	0.8	8
45	A large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability. <i>Annals of Oncology</i> , 2017, 28, v180.	0.6	8
46	Nivolumab-induced celiac-like enteropathy in patient with metastatic renal cell carcinoma: Case report and review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 1689-1693.	0.2	8
47	The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status. <i>Oncolmmunology</i> , 2019, 8, e1562834.	2.1	7
48	GS-09-Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology from two randomised, placebo-controlled phase 3 studies (REACH-2 and REACH). <i>Journal of Hepatology</i> , 2019, 70, e46.	1.8	6
49	Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial. <i>Gastric Cancer</i> , 2019, 22, 577-586.	2.7	6
50	Exploring the factors influencing adherence to oral anticancer drugs in patients with digestive cancer: a qualitative study. <i>Supportive Care in Cancer</i> , 2022, 30, 2591-2604.	1.0	6
51	Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. <i>Liver International</i> , 2021, 41, 2759-2767.	1.9	5
52	Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II Study. <i>Clinical Colorectal Cancer</i> , 2022, 21, e49-e61.	1.0	5
53	Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20Âmg rabeprazole and 20Âmg omeprazole. <i>BMC Gastroenterology</i> , 2014, 14, 128.	0.8	4
54	P1334 : A multicentre, randomised, open-label study comparing the efficacy and safety of two doses of Doxorubicin Transdrug TM to best standard of care in patients with advanced Hepatocellular Carcinoma (HCC) after sorafenib. The relive study. <i>Journal of Hepatology</i> , 2015, 62, S856-S857.	1.8	3

#	ARTICLE	IF	CITATIONS
55	Development of a porcine model for assessment of mucosal repair following endoscopic resection of the lower gastrointestinal tract. <i>Endoscopy International Open</i> , 2017, 05, E1014-E1019.	0.9	3
56	Systematic upper endoscopy concomitant with colonoscopy performed within the colorectal cancer screening program: Impact on the patients' management. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101501.	0.7	3
57	Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101607.	0.7	3
58	Differential biodistribution of oncolytic poxvirus administered systemically in an autochthonous model of hepatocellular carcinoma. <i>Journal of Gene Medicine</i> , 2011, 13, 692-701.	1.4	2
59	Predictive Factors of Chemotherapy Initiation after Biliary Drainage for Advanced Biliary Tract Cancer: A Retrospective Multicenter Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021, 30, 254-258.	0.5	2
60	Oxaliplatin and 5-fluorouracil (FOLFOX) in advanced well-differentiated digestive neuroendocrine tumors: A multicenter national retrospective study from the French Group of Endocrine Tumors (GTE).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4104-4104.	0.8	2
61	Defibrotide for Sinusoidal Obstruction Syndrome and Nodular Regenerative Hyperplasia After Oxaliplatin-Based Hepatic Intra-Arterial Chemotherapy: A Case Report. <i>Clinical Colorectal Cancer</i> , 2022, 21, e98-e101.	1.0	2
62	Combining External Beam Radiotherapy with Measles-Virus Oncolytic Therapy and SAR-020106, A Novel Radiosensitizer, in Head and Neck Cancer Models. <i>Annals of Oncology</i> , 2012, 23, ix537.	0.6	1
63	Jackhammer Esophagus: Clinical, Functional and Therapeutic Data. a Retrospective Multicenter Study in 272 Patients. <i>Gastroenterology</i> , 2017, 152, S323.	0.6	1
64	Survival and prognostic factors analysis of 151 intestinal and pancreatic neuroendocrine tumors: a single center experience. <i>Journal of Gastrointestinal Oncology</i> , 2018, 10, 103-111.	0.6	1
65	P-215 phase 2 HEPANOVA study of tumor treating fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC): Interim safety analysis. <i>Annals of Oncology</i> , 2020, 31, S160.	0.6	1
66	Selective Internal Radiation Combined with Chemotherapy Maintains the Quality of Life in Intrahepatic Cholangiocarcinomas. <i>Current Oncology</i> , 2021, 28, 4530-4541.	0.9	1
67	PRODIGE 25 (FFCD 11-01) - Phase II randomized trial evaluating aflibercept associated with LV5FU2 regimen as first line treatment of non-resectable metastatic colorectal cancers (FOLFA). <i>Annals of Oncology</i> , 2016, 27, vi204.	0.6	0
68	Epidemiological study of histologically proven advanced hepatocholangiocarcinoma: An AGEO multicenter retrospective study. <i>Annals of Oncology</i> , 2017, 28, v241.	0.6	0
69	SP-0334 The Microbiome and treatment side-effects. <i>Radiotherapy and Oncology</i> , 2019, 133, S171.	0.3	0
70	Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort. <i>Digestive and Liver Disease</i> , 2021, , .	0.4	0
71	Esophageal metastasis of stem cell-subtype hepatocholangiocarcinoma: Rare presentation of a rare tumor. <i>World Journal of Gastroenterology</i> , 2018, 24, 870-875.	1.4	0
72	PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4) Tj ETQqO 0 0 rgBT /Overlock 10 Tf 5 TPS3622-TPS3622.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Intensification thérapeutique dans la prise en charge du cancer colorectal métastatique : trichimiothérapie systémique et traitements intra-artériels hépatiques. Colon and Rectum, 2018, 12, 170-177.	0.0	0
74	SYSTEMATIC UPPER ENDOSCOPY CONCOMITANT WITH COLONOSCOPY PERFORMED WITHIN THE COLO-RECTAL CANCER SCREENING PROGRAM: IMPACT ON THE PATIENT-MANAGEMENT STRATEGY. Endoscopy, 2020, 52, .	1.0	0
75	Adhesion of Gastric Cancer Cells to the Enteric Nervous System: Comparison between the Intestinal Type and Diffuse Type of Gastric Cancer. Cancers, 2022, 14, 3296.	1.7	0